Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199767 · ClinicalTrials.gov registry record · Phase 2
SNIFF Multi-Device Study 2
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT04199767 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 13 participants.
The verdict
NCT04199767, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this study will look at the effects of insulin administered intra-nasally on memory, and on blood levels of insulin.
Interventions
- DRUG 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
- DRUG 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2020-11-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04199767
The ClinicalTrials.gov registry entry for NCT04199767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) is the first listed.
NCT04199767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04199767 about?
NCT04199767 is a clinical study titled "SNIFF Multi-Device Study 2". The SNIFF Device study will involve using one of three devices to administer insulin through each participant's nose or intra-nasally, accompanied by a lumbar puncture. This goal of this study is to measure how much insulin the device delivers to the cerebrospinal fluid (CSF). In addition, this stud...
What is the current status of trial NCT04199767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-07-16. Estimated completion is 2020-11-03.
What interventions are being tested in trial NCT04199767?
The interventions under investigation include: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) (DRUG), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company) (DRUG).
Who is sponsoring clinical trial NCT04199767?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.